Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Common Equity (2016 - 2026)

Conmed filings provide 17 years of Common Equity readings, the most recent being $1.0 billion for Q1 2026.

  • On a quarterly basis, Common Equity rose 4.1% to $1.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 billion, a 4.1% increase, with the full-year FY2025 number at $1.0 billion, up 7.31% from a year prior.
  • Common Equity hit $1.0 billion in Q1 2026 for Conmed, down from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.0 billion in Q4 2025 to a low of $673.0 million in Q2 2022.
  • Median Common Equity over the past 5 years was $854.7 million (2024), compared with a mean of $868.2 million.
  • Biggest five-year swings in Common Equity: dropped 9.61% in 2022 and later grew 17.17% in 2024.
  • Conmed's Common Equity stood at $745.5 million in 2022, then rose by 11.89% to $834.2 million in 2023, then rose by 15.4% to $962.7 million in 2024, then grew by 7.31% to $1.0 billion in 2025, then fell by 1.49% to $1.0 billion in 2026.
  • The last three reported values for Common Equity were $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025) per Business Quant data.